ClinicalTrials.gg
Not yet recruitingNCT07552207PKUCH-R12Updated May 4, 2026

Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal Cancer

An interventional study of PET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI in Rectal Cancer, Lymph Node Metastases and PET / MR, sponsored by Peking University Cancer Hospital & Institute. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Peking University Cancer Hospital & Institute · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute — 9 open to participants now, 10 under way, 2 of them phase 3. Rectal Neoplasms · Peking University Cancer Hospital & Institute.

Planned enrollment
11th of 13
30 · median 81
Started
2026
with 2 others
No phase
4 of 16
4 open now
Registered
15th of 16
by date

Among the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 with no phase, and was the 15th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

9 of the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute, or all of them as a file.
02

Study summary

This is a prospective, single-center, diagnostic study designed to compare the accuracy of [68Ga]Ga-CTR-FAPI PET/MRI and [18]F-FDG PET/MRI for the detection of lymph node metastasis in patients with initially untreated, resectable middle to high rectal cancer. The study aims to evaluate whether [68Ga]Ga-CTR-FAPI PET/MRI provides higher sensitivity and specificity than traditional 18F-FDG PET/MRI at both the patient level and the lymph node level.

Read the detailed description

Accurate preoperative staging of colorectal cancer is crucial for formulating treatment plans and improving patient prognosis. While conventional MRI and 18F-FDG PET/MRI are utilized, they face limitations such as false positives due to inflammatory lymph nodes or fibrotic scars. Fibroblast activating protein inhibitor (FAPI) specifically targets tumor-associated fibroblasts, potentially reducing false-positive rates by avoiding non-specific uptake in inflammatory areas.

This study aims to cross-validate the diagnostic efficacy of these two probes through a precise imaging-pathology matching technique. All enrolled patients will sequentially undergo both [68Ga]Ga-CTR-FAPI PET/MRI and 18F-FDG PET/MRI within 30 days prior to radical surgery. Following surgery, fresh mesorectal specimens will be precisely sectioned and matched to preoperative anatomical imaging maps. By leveraging a well-established node-by-node matching and identification methodology with high accuracy, this study ensures the execution of spatial correlation between preoperative radiologic imaging and postoperative microscopic pathology. Through mapping individual lymph nodes, the study will analyze the root causes of false positives and negatives, and extract radiomics features to evaluate their correlation with the tumor microenvironment (e.g., fibroblast density, Ki-67 index).

03

Conditions studied

  • Rectal Cancer
  • Lymph Node Metastases
  • PET / MR

Keywords

  • PET/MR
  • [68Ga]Ga-CTR-FAPI
  • 18F-FDG
  • Lymph Node Staging
  • Radiomics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed rectal adenocarcinoma by pathological .
  • Lower margin of the tumor is ≥ 5 cm and ≤15 cm from the anal verge.
  • Planned to undergo radical surgery.
  • performance status score ≤ 2.
  • Patient is willing to undergo PET/MRI examination.

Exclusion criteria

Exclusion Criteria:

  • History of pelvic radiotherapy or chemotherapy.
  • Concurrent with other malignant tumors or active infections.
  • Pregnant or unable to sign the form.
  • Claustrophobia or inability to tolerate MRI examinations due to other reasons.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Rectal Cancer Patients

    Patients with confirmed middle to high rectal adenocarcinoma who are scheduled for radical surgery.

    Diagnostic Test: PET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI

Interventions

  • Diagnostic testPET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI

    Diagnostic Test: 18F-FDG PET/MRI Description: Patients receive an intravenous injection of 18F-FDG (3.7-5.5 MBq/kg). Diagnostic Test: \[68Ga\]Ga-CTR-FAPI PET/MRI Description: Patients receive an intravenous injection of \[68Ga\]Ga-CTR-FAPI (1.8-3.7 MBq/kg).

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity of Lymph Node Metastasis Detection

    Comparison of the sensitivity and specificity of \[68Ga\]Ga-CTR-FAPI and 18F-FDG PET/MRI in determining lymph node metastasis at both the individual lymph node level and the patient level. Sensitivity is defined as the proportion of imaging-positive and pathology-positive nodes out of all pathology-positive nodes. Specificity is defined as the proportion of imaging-negative and pathology-negative nodes out of all pathology-negative nodes.

    Time frame: Up to 30 days post-surgery

Secondary outcomes

  1. False Positive and False Negative Rates

    Analysis of the false positive and false negative rates of FAPI and FDG imaging, exploring underlying pathological bases such as inflammation or micrometastasis.

    Time frame: Up to 30 days post-surgery

  2. Correlation Between Radiomics Features and Tumor Microenvironment

    Extraction of lymph node radiomics features to evaluate their association with tumor microenvironmental markers, determined via automatic immunohistochemistry scoring.

    Time frame: Up to 30 days post-surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 20 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 27, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552207
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 4, 2026

Study contacts

Minghe Zhao
Contact
dzhao3163@gmail.com
0086-15600896700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion